Neelufar Mozaffarian

Rheumatology

1959 NE Pacific St
Seattle, WA 98195

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion.

Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion.

Journal: mAbs

Published: August 20, 2026

Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies.

Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies.

Journal: Blood reviews

Published: December 27, 2025

Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis.

Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis.

Journal: The journal of allergy and clinical immunology. Global

Published: March 18, 2023

Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study.

Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study.

Journal: Rheumatology (Oxford, England)

Published: October 29, 2021

Randomized, double-blind, placebo-controlled trial of ISC 17536, an oral inhibitor of transient receptor potential ankyrin 1, in patients with painful diabetic peripheral neuropathy: impact of preserved small nerve fiber function.

Randomized, double-blind, placebo-controlled trial of ISC 17536, an oral inhibitor of transient receptor potential ankyrin 1, in patients with painful diabetic peripheral neuropathy: impact of preserved small nerve fiber function.

Journal: Pain

Published: February 19, 2021

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.

Journal: Annals of the rheumatic diseases

Published: September 30, 2020

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.

Journal: Annals of the rheumatic diseases

Published: September 30, 2020

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.

Journal: JAMA

Published: July 24, 2019

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.

Journal: Lancet (London, England)

Published: September 14, 2018

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.

Journal: Lancet (London, England)

Published: September 06, 2018

Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives.

Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives.

Journal: Patient preference and adherence

Published: October 28, 2016

Sjögren's syndrome: managed care data from a large United States population highlight real-world health care burden and lack of treatment options.

Sjögren's syndrome: managed care data from a large United States population highlight real-world health care burden and lack of treatment options.

Journal: Clinical and experimental rheumatology

Published: March 07, 2016

Showing 1-12 of 15

Last Updated: 09/26/2026